India, June 30 -- Nuvectis Pharma, Inc. (NVCT), a clinical-stage biopharmaceutical company, priced an offering of 5 million shares at $20.00 per share, with expected gross proceeds of $100 million.The offering is expected to close on or about July 1, 2026.
Nuvectis' development pipeline includes NXP100, an investigational complement Factor B inhibitor for complement-mediated diseases, and oncology drug candidates NXP900 and NXP200 for advanced cancers, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer.
In addition, Nuvectis has also granted the underwriters a 30-day option to purchase up to 0.75 million shares at the public offering price less underwriting discounts and commissions.
Nuve...